Asuka Pharmaceutical’s consolidated net sales for the Fiscal Year ending March 2026 were \u00a571.1 billion, a 10.9% increase YoY. Operating profit was \u00a55.8 billion, up 9.4%, and net income was \u00a55.4 billion, a 6.3% increase. The company also expanded research and development expenses and overseas operations, strengthening its growth foundation moving forward.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4886-20260519-01.pdf","jir_short_summary":"Asuka Pharmaceutical's consolidated net sales for the Fiscal Year ending March 2026 were \u00a571.1 billion, a 10.9% increase YoY. Operating profit was \u00a55.8 billion, up 9.4%, and net income was \u00a55.4 billion, a 6.3% increase. The company also expanded research and development expenses and overseas operations, strengthening its growth foundation moving forward.","jir_summary":"### Performance Overview\nAsuka Pharmaceutical's consolidated results for the fiscal year ending March 2026 totaled net sales of \u00a571.1 billion (up 10.9% YoY), operating profit of \u00a55.8 billion (up 9.4%), and net income of \u00a55.4 billion (up 6.3%). The company achieved increased revenue and profit driven by steady growth in the pharmaceutical business and the addition of new overseas subsidiaries. Research and development expenses also increased, actively promoting clinical trials and partnership activities for new drugs.\n\n### Future Outlook and Shareholder Returns\nBased on its Mid-term Management Plan 2025, Asuka Pharmaceutical projects continued growth with net sales exceeding \u00a573 billion and operating profit over \u00a56.0 billion in the fiscal year ending March 2027. The company plans to accelerate overseas expansion and new drug development. It intends to pay an annual dividend of \u00a560, implementing a progressive dividend policy. Under the long-term vision 'ASKA VISION 2035,' the company aims to achieve sustainable growth while providing shareholder returns.","jir_financial_highlights":"Net Sales: \u00a5711,127 million (up 10.9% YoY)\nOperating Profit: \u00a55,834 million (up 9.4% YoY)\nNet Income Attributable to Owners of Parent: \u00a55,424 million (up 6.3% YoY)","jir_category":"","jir_hashtags":"#AsukaPharmaceutical, #IR, #JapaneseStocks","jir_key_figures":"Net sales: \u00a5711,127 million (up 10.9% YoY)\nOperating profit: \u00a55,834 million (up 9.4% YoY)\nNet income attributable to owners of parent: \u00a55,424 million (up 6.3% YoY)","jir_meta_title":"\u3010Asuka Pharmaceutical\u30112026 Financial Results\uff5cNet Sales \u00a571.1 Billion, Increased Revenue and Profit","jir_meta_description":"An overview of Asuka Pharmaceutical's consolidated financial results for the fiscal year ending March 2026. Achieved net sales of \u00a571.1 billion, operating profit of \u00a55.8 billion, and net income of \u00a55.4 billion, with strategic growth initiatives also introduced.","jir_og_title":"\u3010Asuka Pharmaceutical\u30112026 Financial Results\uff5cNet Sales \u00a571.1 Billion, Increased Revenue and Profit","jir_og_description":"This article covers Asuka Pharmaceutical's FY2026 financial overview and future outlook. The company achieved \u00a571.1 billion in sales, increased revenue and profit, and shared upcoming plans.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-52927","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n